High Efficacy of Imatinib for Recurrent Gastrointestinal Stromal Tumor in the Jejunum: A Case Report

Journal of Nippon Medical School

Volumn 71, Issue 2, 2004, Pages 114-119

  Yokoi, Kimiyoshi ^a   Tanaka, Noritake ^a   Kyound, Shoji ^a   Ishikawa, Noriyuki ^a   Seya, Tomoko ^a   Shirakawa, Takashi ^a   Takahashi, Yoshiyuki ^a   Ohaki, Yoshiharu ^a   Yamashita, Kiyohiko ^a   Tajiri, Takashi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

c kit; GIST; Imatinib; Recommended dosage; STI571

Indexed keywords

DOMPERIDONE; IMATINIB;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG EFFICACY; EDEMA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; JEJUNUM TUMOR; LEUKOPENIA; NAUSEA; RECURRENT DISEASE; REOPERATION; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; JEJUNAL NEOPLASMS; MESENCHYMOMA; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 19244365510     PISSN: 13454676     EISSN: None     Source Type: Journal    
DOI: 10.1272/jnms.71.114     Document Type: Article

References (14)

1. Stout AP: Bizarre smooth muscle tumors of stomach. Cancer 1962; 15: 400-409.
2. Appelman HD: Smooth muscle tumors of the gastrointestinal tract. What we know now that Stout didn't know. Am J Surg Pathol 1986; 10 (supple): 83-99.
3. Mazur MT, Clark HB: Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-519.
4. Rosal J: Stromal tumors. Ackerman's surgical pathology, 8th edn (Rosai J, ed), 1996; pp 645-647, Mosby-Year Book, Inc, Chicago.
5. Miettinen M, Virolainen M, Sarlomo-Rikala M: Gastrointestinal stromal tumors-Value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995; 19: 207-216.
6. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
7. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
8. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
10. WHO: WHO handbook for reporting results of cancer treatment. 1979; No. 48, World Health Organization, Offset Publication, Geneva.
11. Cancer Therapy Evaluation Program: Common toxicity criteria manual: common toxicity criteria, version 2.0. 1999, National Cancer Institute, Bethesda.
12. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
13. van Oosterom AT, Judson I, Verweij Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phaseIstudy. Lancet 2001; 358: 1421-1423.
14. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.